3-(Hydroxymethyl)benzoyl chloride | 1370010-57-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(Hydroxymethyl)benzoyl chloride
• CAS: 1370010-57-3
• 化学式: C₈H₇ClO₂
• 分子量: 170.595
• InChiKey: NFWDJXPNFKVUEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(Hydroxymethyl)benzoyl chloride 在 吡啶 、 硫酸 、 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 N-butyl-N-[5-[3-(hydroxymethyl)phenyl]-1,3,4-thiadiazol-2-yl]-4-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Discovery of thiadiazole amides as potent, S1P3-sparing agonists of sphingosine-1-phosphate 1 (S1P1) receptor

  摘要：

  High-throughput screening of GSK compound collection led to the discovery of a novel series of thiadiazole amides as potent and S1P(3)-sparing sphingosine-1-phosphate 1 (S1P(1)) receptor agonists. Synthesis, structure and activity relationship, selectivity, and some developability properties are described. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.016

文献信息

• PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF
  申请人：INNOV17 LLC

  公开号：US20170298060A1

  公开（公告）日：2017-10-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗与视黄酸受体相关孤儿受体调节的疾病和紊乱是有用的。
• INDAZOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF
  申请人：INNOV17 LLC

  公开号：US20160024057A1

  公开（公告）日：2016-01-28

  Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

  本文提供了以下化合物的公式（I）和（II）以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的制药组合物，可用于治疗视黄酸受体相关孤儿受体调节的疾病和疾病。
• AZAINDOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF
  申请人：INNOV17 LLC

  公开号：US20160024086A1

  公开（公告）日：2016-01-28

  Provided herein are compounds of the formulas (I) and (II): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

  本文提供的化合物公式(I)和(II)以及其药学上可接受的盐，其中取代基与规范中所披露的相同。这些化合物及其含量的制药组合物，用于治疗视黄酸受体相关孤儿受体调节的疾病和障碍。
• PYRROLE COMPOUND
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：EP2808324A1

  公开（公告）日：2014-12-03

  Provided is a highly safe and effective compound represented by the following general formula (1) or a salt thereof which acts on tubulin and has an anticancer effect, wherein Ar represents an aryl group or a heteroaryl group; Z1, Z2, Z3, and Z4 each independently represent CH, a nitrogen atom, an oxygen atom, or a sulfur atom; R1 represents a hydrogen atom, a halogen atom, an alkyl group, or the like; R2 and R3 are the same or different and each represent a hydrogen atom, a halogen atom, a carboxyl group, or the like; n units of R4 are the same or different and each represent a hydrogen atom, an alkyl group, or the like; and n represents a number of 0 to 4.

  本发明提供了一种由以下通式（1）代表的高度安全有效的化合物或其盐，该化合物作用于微管蛋白并具有抗癌效果，其中 Ar 代表芳基或杂芳基；Z1、Z2、Z3 和 Z4 各自独立地代表 CH、氮原子、氧原子或硫原子；R1 代表氢原子、卤素原子、烷基或类似物；R2 和 R3 相同或不同，各自代表氢原子、卤素原子、羧基或类似物；R4 的 n 个单元相同或不同，各自代表氢原子、烷基或类似物；以及 n 代表 0 至 4 的数字。
• US20140343017A1
  申请人：——

  公开号：US20140343017A1

  公开（公告）日：2014-11-20